Palvella Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Palvella Therapeutics, Inc. (PVLA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 0.18% for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-31.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2021-03-31
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2017-09-30 was 2.02%, a 49.63% increase year-over-year.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2017-06-30 was 199.00%, a 33.56% increase year-over-year.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2017-03-31 was 2.16%, a 34.16% increase year-over-year.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2016-09-30 was 1.35%, a 28.57% decline year-over-year.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2020 was 0.18%.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2017 was 2.22%, a 6.73% increase from fiscal 2016.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2016 was 2.08%, a 10.05% increase from fiscal 2015.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2015 was 1.89%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|---|---|
| 2020-12-31 | 0.18% 10-K · filed 2021-03-31 | |||||
| 2017-12-31 | 2.22% 10-K · filed 2018-03-15 | |||||
| 2017-09-30 | 2.02% 10-Q · filed 2017-11-13 | 2.16% 10-Q · filed 2017-11-13 | ||||
| 2017-06-30 | 199.00% 10-Q · filed 2017-08-11 | 216.00% 10-Q · filed 2017-08-11 | ||||
| 2017-03-31 | 2.16% 10-Q · filed 2017-05-15 | |||||
| 2016-12-31 | 2.08% 10-K · filed 2018-03-15 | |||||
| 2016-09-30 | 1.35% 10-Q · filed 2017-11-13 | 1.61% 10-Q · filed 2017-11-13 | ||||
| 2016-06-30 | 149.00% 10-Q · filed 2017-08-11 | 1.49% 10-Q · filed 2016-08-11 | 161.00% 10-Q · filed 2017-08-11 | 1.61% 10-Q · filed 2016-08-11 | ||
| 2016-03-31 | 1.61% 10-Q · filed 2017-05-15 | |||||
| 2015-12-31 | 1.89% 10-K · filed 2017-03-30 | |||||
| 2015-09-30 | 1.89% 10-Q · filed 2016-11-10 | 1.89% 10-Q · filed 2016-11-10 | ||||
| 2015-06-30 | 1.79% 10-Q · filed 2016-08-11 | 1.79% 10-Q · filed 2016-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |